NCT02242331已完成不适用
Risk of Morning Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 19,805
- 主要终点
- Change from baseline in blood pressure
研究概览
简要总结
This post-marketing surveillance study is designed to supplement under conditions of normal clinical practice data on safety, tolerability and efficacy of Micardis® collected in clinical studies with special emphasis on the control of blood pressure in the morning before intake of the next antihypertensive drug
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Essential hypertension
- •At least 18 years of age
排除标准
- 未提供
研究组 & 干预措施
essential hypertension patients
干预措施: Micardis® (Drug)
结局指标
主要结局
Change from baseline in blood pressure
时间窗: Baseline, after 3 months
with special emphasis on the morning blood pressure, before intake of the next antihypertensive treatment
Changes from baseline in pulse rate
时间窗: Baseline, after 3 months
Number of patients with adverse events
时间窗: up to 3 months
次要结局
- Assessment of tolerability by investigator on a 5-point scale(after 3 months)
- Assessment of efficacy by investigator on 5- point scale(after 3 months)
研究者
相似试验
招募中
不适用
An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac ArrhythmiasNCT04750798Biosense Webster, Inc.8,000
已完成
不适用
Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)HypertensionNCT02262611Boehringer Ingelheim266
暂停
不适用
A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical PracticeChronic Lymphocytic Leukemia (CLL)NCT03659669AbbVie272
进行中（未招募）
不适用
Avenir® Cemented Hip Stem - PMCFPrimary OsteoarthritisPost-Traumatic Osteoarthritis of HipFemoral Neck FracturesFemoral Head NecrosisSequelae From Previous Hip SurgeryOsteotomiesCongenital Hip DysplasiaNCT03396224Zimmer Biomet100
已完成
4 期
Post-Market Surveillance Study of the TM Ardis Interbody Fusion SystemDegenerative Disc DiseaseNCT02429908Zimmer Biomet80